Background: The human papillomavirus (hpv) is a common sexually transmitted infection and a primary cause of cervical cancer. The Government of Canada has set a target of reaching 90% hpv vaccine coverage among adolescents by 2025. Here, we examine hpv vaccine uptake in school-based immunization programs across Canada and explore how achieving the 90% target could affect the future incidence of cervical cancer, mortality, and health system expenditures in a cohort of Canadian women. Methods: Data for hpv vaccine uptake in the most recent reported school year available in each jurisdiction were provided in 2017 by jurisdictional school-based immunization programs and were used to estimate a national weighted average of 67%. The OncoSim microsimulation model (version 2.5) was used to compare 3 different levels of hpv vaccine uptake (0%, 67%, 90%) on health and economic outcomes for a hypothetical cohort of all 5- to 10-year-old girls in Canada in 2015. Results: Vaccine uptake for girls in school-based programs varied from 55.0% to 92.0% in the jurisdictions reviewed. The OncoSim model projects that increasing uptake to 90% from 67% would result in a 23% reduction in cervical cancer incidence rates (to 3.1 cases from 4.0 cases per 100,000, averaged across the lifetime of the cohort) and a 23% decline in the average annual mortality rate (to 1.0 deaths from 1.3 deaths per 100,000). Finally, the model projects that the health system will incur a cost of $9 million (1% increase) during the lifetime of the cohort if uptake is increased to 90% from 67%. Costs are discounted (1.5%) and expressed in 2016 Canadian dollars. Costs reflect the payer perspective. Conclusions: Our model shows that increasing hpv vaccine uptake to 90% from current levels for girls in school-based immunization programs could result in substantial reductions in the future incidence and mortality rates for cervical cancer in Canada.
Background: The human papillomavirus (hpv) is a common sexually transmitted infection and a primary cause of cervical cancer. The Government of Canada has set a target of reaching 90% hpv vaccine coverage among adolescents by 2025. Here, we examine hpv vaccine uptake in school-based immunization programs across Canada and explore how achieving the 90% target could affect the future incidence of cervical cancer, mortality, and health system expenditures in a cohort of Canadian women. Methods: Data for hpv vaccine uptake in the most recent reported school year available in each jurisdiction were provided in 2017 by jurisdictional school-based immunization programs and were used to estimate a national weighted average of 67%. The OncoSim microsimulation model (version 2.5) was used to compare 3 different levels of hpv vaccine uptake (0%, 67%, 90%) on health and economic outcomes for a hypothetical cohort of all 5- to 10-year-old girls in Canada in 2015. Results: Vaccine uptake for girls in school-based programs varied from 55.0% to 92.0% in the jurisdictions reviewed. The OncoSim model projects that increasing uptake to 90% from 67% would result in a 23% reduction in cervical cancer incidence rates (to 3.1 cases from 4.0 cases per 100,000, averaged across the lifetime of the cohort) and a 23% decline in the average annual mortality rate (to 1.0 deaths from 1.3 deaths per 100,000). Finally, the model projects that the health system will incur a cost of $9 million (1% increase) during the lifetime of the cohort if uptake is increased to 90% from 67%. Costs are discounted (1.5%) and expressed in 2016 Canadian dollars. Costs reflect the payer perspective. Conclusions: Our model shows that increasing hpv vaccine uptake to 90% from current levels for girls in school-based immunization programs could result in substantial reductions in the future incidence and mortality rates for cervical cancer in Canada.
Entities:
Keywords:
OncoSim; cancer control; cancer modelling; cancer outcome projections; cervical cancer; hpv vaccination
Authors: Johannes A Bogaards; Maria Xiridou; Veerle M H Coupé; Chris J L M Meijer; Jacco Wallinga; Johannes Berkhof Journal: Am J Epidemiol Date: 2010-03-15 Impact factor: 4.897
Authors: Michelle J Khan; Philip E Castle; Attila T Lorincz; Sholom Wacholder; Mark Sherman; David R Scott; Brenda B Rush; Andrew G Glass; Mark Schiffman Journal: J Natl Cancer Inst Date: 2005-07-20 Impact factor: 13.506
Authors: Veerle M H Coupé; Joost van Ginkel; Hester E de Melker; Peter J F Snijders; Chris J L M Meijer; Johannes Berkhof Journal: Int J Cancer Date: 2009-02-15 Impact factor: 7.396
Authors: William K Evans; Michael C Wolfson; William M Flanagan; Janey Shin; John Goffin; Anthony B Miller; Keiko Asakawa; Craig Earle; Nicole Mittmann; Lee Fairclough; Jillian Oderkirk; Philippe Finès; Stephen Gribble; Jeffrey Hoch; Chantal Hicks; D Walter R Omariba; Edward Ng Journal: Int J Technol Assess Health Care Date: 2013-03-20 Impact factor: 2.188
Authors: Beatriz Serrano; Laia Alemany; Sara Tous; Laia Bruni; Gary M Clifford; Thomas Weiss; Francesc Xavier Bosch; Silvia de Sanjosé Journal: Infect Agent Cancer Date: 2012-12-29 Impact factor: 2.965
Authors: Yibing Ruan; Abbey E Poirier; Joy Pader; Keiko Asakawa; Chaohui Lu; Saima Memon; Anthony B Miller; Stephen D Walter; Paul J Villeneuve; Will D King; Karena D Volesky; Leah Smith; Prithwish De; Christine M Friedenreich; Darren R Brenner Journal: Can J Public Health Date: 2021-05-25